Progenity Joins Global Call to Raise Awareness of Preeclampsia in Pregnancy on World Preeclampsia Day – May 22nd marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
Dermavant Sciences: Dermavant Announces Appointment of Michael Swartzburg as Chief Financial Officer
- Over 20 Years of Combined Experience in Global Finance Leadership, Audit, and Advisory Roles in the Biopharmaceutical Industry -
Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced the appointment of Michael Swartzburg as Chief Financial Officer. Mr. Swartzburg brings extensive finance expertise, with over 20 years of leadership within the biotechnology and healthcare space. Michael is an incredibly talented senior financial executive who has spent the greater part of his career within the biotechnology and healthcare industries, said Todd Zavodnick, Chief Executive Officer of Dermavant. Michael s experience in directing and managing growth at previous biopharmaceutical companies is critical as we enter our next phase of development and plan for the commercial
(0)
- Approximately One in Five Tapinarof Patients Achieved At Least 90% Disease Clearance -
- A Significantly Higher Portion of Psoriasis Patients Experienced Clinically Meaningful Improvements in Itch with Tapinarof Compared to Vehicle -
- Improvements in DLQI Exceeded MCID at Week 12 with Statistical Significance Compared to Vehicle -
- Data Will Be Included in NDA Submission for Tapinarof, Expected Mid-2021 -
Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, will present data from its two pivotal Phase 3 trials for tapinarof for the treatment of psoriasis in adults, PSOARING 1 (tapinarof 1%, n=340; vehicle, n=170) and PSOARING 2 (tapinarof 1%, n=343; vehicle, n=172), at the American Academy of Dermatology Virtual Meeting Experience 2021 (AAD VMX 2021) on April 23-25, 2021.
Dermavant to Showcase PASI90, Itch and Quality of Life Data from Phase 3 Pivotal Trials for Tapinarof at AAD VMX 2021 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Dermavant Sciences: Dermavant Announces Tapinarof Data Presentations at the AAD VMX 2021
Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced that two abstracts from Dermavant s two pivotal Phase 3 trials for tapinarof for the treatment of psoriasis in adults, PSOARING 1 and PSOARING 2, will be presented during the upcoming American Academy of Dermatology Virtual Meeting Experience 2021 (AAD VMX 2021), on April 23-25, 2021.
Tapinarof is being developed as a novel, once-daily therapeutic aryl hydrocarbon receptor modulating agent (TAMA), cosmetically elegant, steroid-free topical cream for the treatment of plaque psoriasis and atopic dermatitis.
The following posters will be viewable on the conference platform for the entirety of the conference: